Nutritional composition, preparation method thereof and application of nutritional composition in improving sleep

Abstract

The present invention relates to a nutritional composition, a process for its preparation and its use in improving sleep. The nutritional composition comprises: 90-95% by mass of milk-based powder selected from one or more of the following: whole milk powder, milk protein powder, bovine colostrum powder, whey protein powder, demineralized whey powder and skimmed milk powder; 0.5 to 6.0 mass percent of gamma-aminobutyric acid; 0.5 to 6.0 mass percent of L-theanine; 0.5-4% by mass of sodium carboxymethyl cellulose; 0.05 to 1.0 mass percent of silicon dioxide; 0.01%-1.0% by mass of milk protein peptide; 0.01-1.0% by mass of colostrum peptide powder; 0.05%-1.0% by mass of a compound plant extract; and 0.01-1.0% by mass of a sweetening agent selected from stevioside and / or mogroside.

Description

Technical Field

[0001] This invention generally relates to the field of nutritional compositions. Specifically, this invention relates to nutritional compositions, methods for their preparation, and their uses in improving sleep. Background Technology

[0002] Sleep disorders include difficulty falling asleep at night, poor sleep quality, early awakening, and disruption of the circadian rhythm. Sleep disorders can lead to daytime fatigue, poor learning and work efficiency, impaired memory, and affect various bodily functions such as immune and cognitive functions. They can even cause metabolic disorders and trigger various diseases. Sleep is crucial for both an individual's mental and physical health. Epidemiological surveys show that approximately 10%–15% of the world's population suffers from insomnia, and about 25%–35% suffer from transient or occasional insomnia. Sleep disorders place a heavy burden on socioeconomic and healthcare systems. With increasing societal attention to sleep disorders, treatment methods for various sleep disorders are emerging, mainly divided into non-pharmacological and pharmacological treatments. Currently, the most effective treatments and methods for improving sleep mostly involve the use of chemical drugs. Although these drugs have advantages such as rapid onset of action and clear efficacy, they also have adverse effects such as addiction and drug tolerance. Long-term use may also lead to adverse consequences such as amnesia and cognitive impairment, thus limiting their use. In order to develop effective and safer ingredients and products for improving sleep, people are turning their attention to various natural ingredients for related research and experimentation.

[0003] Therefore, it is still necessary to provide a nutritional composition that can improve sleep quality.

[0004] In addition, for nutritional compositions that improve sleep, it is desirable that they have excellent uniformity and solubility stability in order to achieve better sleep-promoting effects, a wider range of applicable people, and a better user experience. Summary of the Invention

[0005] This invention was made in view of the aforementioned problems existing in the prior art.

[0006] In a first aspect, the present invention relates to a nutritional composition that has a significant effect on improving sleep.

[0007] In a second aspect, the present invention relates to a method for preparing a nutritional composition according to the first aspect of the present invention.

[0008] In a third aspect, the present invention relates to the use of a nutritional composition according to the first aspect of the present invention for improving sleep efficacy.

[0009] Specifically, the present invention is achieved by the following:

[0010] 1. A nutritional composition comprising or consisting of the following:

[0011] Milk base powder of 90-95% by weight, selected from one or more of the following: whole milk powder, milk protein powder, bovine colostrum powder, whey protein powder, demineralized whey powder, and skim milk powder.

[0012] 0.5-6.0% by mass of γ-aminobutyric acid,

[0013] 0.5-6.0% L-theanine by mass

[0014] 0.5-4% sodium carboxymethyl cellulose by weight,

[0015] 0.05-1.0% by mass of silicon dioxide,

[0016] 0.01-1.0% by weight of milk protein peptides,

[0017] 0.01-1.0% by weight of colostrum peptide powder,

[0018] 0.05-1.0% by weight of compound plant extracts,

[0019] 0.01-1.0% by weight of a sweetener selected from steviol glycosides and / or mogrosides.

[0020] 2. The nutritional composition as described in Project 1, wherein the nutritional composition comprises 1-3% by mass, for example 2% by mass, of γ-aminobutyric acid.

[0021] 3. The nutritional composition as described in any one of items 1-2, wherein the nutritional composition comprises 1-3% by weight, for example 2% by weight, of L-theanine.

[0022] 4. The nutritional composition as described in any one of items 1-3, wherein the mass ratio of γ-aminobutyric acid to L-theanine is 6:1 to 1:6, preferably 3:1 to 1:3, more preferably 3:1 to 1:1, and even more preferably 1:1.

[0023] 5. The nutritional composition as described in any one of items 1-4, wherein the sweetener is steviol glycoside, or a combination of steviol glycoside and mogroside, preferably steviol glycoside.

[0024] 6. The nutritional composition as described in any one of items 1-5, wherein the nutritional composition comprises:

[0025] 93-94% quality emulsion base powder,

[0026] 1.9-2.1% by mass of γ-aminobutyric acid,

[0027] 1.9-2.1% L-theanine by mass

[0028] 1.4-1.6% sodium carboxymethyl cellulose by weight

[0029] 0.15-0.25% silica by mass

[0030] 0.05-0.15% by weight of milk protein peptides,

[0031] 0.05-0.15% colostrum peptide powder by weight,

[0032] 0.10-0.20% by weight of compound plant extracts,

[0033] 0.05-0.15% by weight of steviol glycosides.

[0034] 7. The nutritional composition as described in any one of items 1-6, wherein the compound plant extract comprises or is two or more of the following: tea theanine, lily powder, passion fruit powder, jujube seed powder, and saffron extract, preferably comprising or is tea theanine, lily powder, passion fruit powder, jujube seed powder, and saffron extract; preferably wherein the mass ratio of tea theanine: lily powder: passion fruit powder: jujube seed powder: saffron extract is (0.5-4.0):1: (0.5-2.0):(0.5-2.0): (0.05-1.0), more preferably (1.0-2.0):1: (0.5-1.0): (0.5-1.5): (0.1-0.5), and more preferably 1.6:1:0.8:1:0.2.

[0035] 8. A method for preparing a nutritional composition as described in any one of items 1-7, comprising the following steps:

[0036] (1) Ingredients: Provide the formula amount of milk base powder, γ-aminobutyric acid, L-theanine, sodium carboxymethyl cellulose, silicon dioxide, milk protein peptides, colostrum peptide powder, compound plant extracts and sweeteners;

[0037] (2) Premixed:

[0038] (2-1) Disperse and granulate the formulated amounts of silica, milk protein peptides, colostrum peptide powder, compound plant extracts, and sweeteners to obtain premix A; and

[0039] (2-2) Disperse and granulate the formulated amounts of γ-aminobutyric acid and L-theanine to obtain premix B;

[0040] (3) Sieving: The emulsion base powder, premix A, premix B, and sodium carboxymethyl cellulose are passed through a vibrating screen in n batches. The resulting materials enter the mixing drum.

[0041] - n is a positive integer of 3 or greater.

[0042] - Sodium carboxymethyl cellulose is added in the i-th batch, where i is a positive integer ≤ n / 2;

[0043] - In each of batches 1 to n-2, when sodium carboxymethyl cellulose is not present, the ingredients are added in the order of 1 / n formula amount of emulsion powder, 1 / n formula amount of premix A, and 1 / n formula amount of premix B; and when sodium carboxymethyl cellulose is present, the ingredients are added in the order of 1 / n formula amount of emulsion powder, 1 / n formula amount of premix A, 1 / n formula amount of premix B, and formula amount of sodium carboxymethyl cellulose.

[0044] -In the n-1th batch, the emulsion base powder (1 / 2n of the formula amount), premix A (1 / n of the formula amount), and premix B (1 / n of the formula amount) are added in that order;

[0045] -In the nth batch, the ingredients are added in the following order: 1 / 2n of the formula amount of emulsion base powder, 1 / n of the formula amount of premix A, 1 / n of the formula amount of premix B, and 1 / n of the formula amount of emulsion base powder.

[0046] (4) Dry mixing: The materials obtained in the mixing cylinder in step (3) are dry mixed to obtain the nutritional composition.

[0047] 9. The method as described in Item 8, wherein the granulation in steps (2-1) and (2-2) is performed at the same or different, preferably the same, operating frequencies and said operating frequencies are each independently 10-60 Hz, for example 30-35 Hz; and the granulation in steps (2-1) and (2-2) is performed using the same or different, preferably the same, sieves and said sieves are each independently 10-60 mesh, for example 20-40 mesh.

[0048] 10. The method described in any one of items 8-9, wherein...

[0049] n=3, and in step (3), the emulsion base powder, premix A, premix B and sodium carboxymethyl cellulose are added in the following order:

[0050] Batch 1: 1 / 3 of the formula amount of emulsion base powder, 1 / 3 of the formula amount of premix A, 1 / 3 of the formula amount of premix B, and the formula amount of sodium carboxymethyl cellulose.

[0051] Batch 2: 1 / 6 of the formula amount of emulsion base powder, 1 / 3 of the formula amount of premix A, and 1 / 3 of the formula amount of premix B.

[0052] Batch 3: 1 / 6 of the formula amount of emulsion base powder, 1 / 3 of the formula amount of premix A, 1 / 3 of the formula amount of premix B, and 1 / 3 of the formula amount of emulsion base powder.

[0053] 11. The method described in any one of items 8-10, wherein...

[0054] n=4, and in step (3), the emulsion base powder, premix A, premix B and sodium carboxymethyl cellulose are added in the following order:

[0055] Batch 1: 1 / 4 of the formula amount of base material, 1 / 4 of the formula amount of premix A, and 1 / 4 of the formula amount of premix B.

[0056] Batch 2: 1 / 4 of the formula amount of base material, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, and sodium carboxymethyl cellulose.

[0057] Batch 3: 1 / 8 of the formula amount of base material, 1 / 4 of the formula amount of premix A, and 1 / 4 of the formula amount of premix B.

[0058] Batch 4: 1 / 8 of the formula amount of base material, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, and 1 / 4 of the formula amount of base material.

[0059] 12. The method described in any of items 8-11, wherein the vibrating sieve used in step (3) is 10-30 mesh.

[0060] 13. Use of a nutritional composition as described in any one of items 1-7 or prepared as described in any one of items 8-12 in improving sleep.

[0061] The inventors have discovered that the nutritional composition of the present invention has excellent sleep-improving effects, excellent solution stability after brewing, and excellent taste; and when the nutritional composition is prepared by the method of the present invention, the nutritional composition has a more uniform composition. Attached Figure Description

[0062] Figure 1 This shows the dynamic change in transmittance of the composition sample prepared in Example 1 during centrifugation.

[0063] Figure 2 This image shows the state of the composition sample prepared in Example 1 after a stability test.

[0064] Figure 3 This shows the dynamic change in transmittance of the composition sample prepared in Comparative Example 1 during centrifugation.

[0065] Figure 4 Images showing the state of the composition sample prepared in Comparative Example 1 after stability testing.

[0066] Figure 5 This shows the dynamic change in transmittance of the composition sample prepared in Comparative Example 2 during centrifugation.

[0067] Figure 6Images showing the state of the composition sample prepared in Comparative Example 2 after stability testing.

[0068] Figures 7A-7D This shows the survival rate of zebrafish exposed to different concentrations of samples for 96 hours. Figure 7A ), heart rate ( Figure 7B ), deformity rate ( Figure 7C ) and phenotype ( Figure 7D ) Changes.

[0069] Figures 8A-8D This displays statistics on the autonomous behavior of zebrafish after different sample treatments.

[0070] Figure 9 This shows the relative expression levels of the GABA-A receptor gene in zebrafish under different sample exposure conditions.

[0071] Figure 10 This shows the GABA content of zebrafish under different exposure conditions.

[0072] Figure 11 This indicates the subjects' self-perceived level of acceptance after using the sample.

[0073] Figure 12 The changes in the Pittsburgh Sleep Quality Index were shown before and after subjects used composition 1. Detailed Implementation

[0074] Unless otherwise specified, the technical terms in this specification have the same meaning as those generally understood by those skilled in the art; however, in case of any conflict, the definitions in this specification shall prevail.

[0075] As used herein, the following terms have the following meanings.

[0076] The term "teenager" refers to people aged 7-17.

[0077] The term "adult" refers to a person who is 18 years of age or older.

[0078] The term "young people" refers to people aged 18-40.

[0079] The term "teenager" refers to people aged 7 to 40.

[0080] The term "middle-aged" refers to people aged 41-65.

[0081] The term “elderly” or “senior citizen” refers to people who are 65 years of age or older.

[0082] In this application, “non-therapeutic use” and “non-medical therapeutic use” are synonymous and can be used interchangeably, referring to use for nutrition and / or health care through daily consumption.

[0083] Furthermore, in the context of this invention, the terms "comprising" or "including" do not exclude other possible elements. The compositions of this invention (including the various embodiments described herein) may include, consist of, or substantially consist of the following elements: the essential elements and necessary limitations of the invention as described herein, and any other or optional ingredients, components, or limitations as described herein or as otherwise desired.

[0084] Those skilled in the art will understand that, unless otherwise specified, in this application, a number containing n significant digits after the decimal point actually also includes the result of rounding a number containing more significant digits after the decimal point to n significant digits. For example, 1.0 actually covers all numbers in the range from greater than or equal to 0.95 to less than 1.05; 0.15 actually covers all numbers in the range from greater than or equal to 0.145 to less than 0.155; 0.156 actually covers all numbers in the range from greater than or equal to 0.1555 to less than 0.1565, and so on.

[0085] Unless otherwise specified, in this application, when referring to the amount or ratio of a substance or component, it is in terms of mass.

[0086] It should be noted that the various aspects, features, implementation methods, experimental examples, and advantages described in this application are compatible and / or can be combined together.

[0087] This invention relates to nutritional compositions, methods for their preparation, and their use in improving sleep.

[0088] The present invention will be described in detail below.

[0089] Nutritional composition

[0090] In a first aspect, the present invention relates to a nutritional composition comprising or consisting of the following:

[0091] Milk base powder of 90-95% by weight, selected from one or more of the following: whole milk powder, milk protein powder, bovine colostrum powder, whey protein powder, demineralized whey powder, and skim milk powder.

[0092] 0.5-6.0% by mass of γ-aminobutyric acid,

[0093] 0.5-6.0% L-theanine by mass

[0094] 0.5-4% sodium carboxymethyl cellulose by weight,

[0095] 0.05-1.0% by mass of silicon dioxide,

[0096] 0.01-1.0% by weight of milk protein peptides,

[0097] 0.01-1.0% by weight of colostrum peptide powder,

[0098] 0.05-1.0% by weight of compound plant extracts,

[0099] 0.01-1.0% by weight of a sweetener selected from steviol glycosides and / or mogrosides.

[0100] In this application, unless otherwise specified, the mass percentage of each component in the nutritional composition is relative to the total mass of the nutritional composition, or relative to the total mass (sum of masses) of the components.

[0101] The applicant discovered that when the nutritional composition has the defined components, it has a significant effect on improving sleep.

[0102] In this embodiment, the milk base powder may be appropriately selected according to the intended use (e.g., target population) without particular limitation, and may be selected, for example, from one or more of the following: whole milk powder, milk protein powder, bovine colostrum powder, whey protein powder, demineralized whey powder, and skim milk powder, preferably from one or more of the following: whole milk powder, milk protein powder, and bovine colostrum powder. The milk protein powder may be, for example, casein powder.

[0103] In an embodiment, the nutritional composition comprises 90-95% by weight of a milk base powder. For example, relative to the total mass of the nutritional composition, the milk base powder may be, for example, 90.00, 90.05, 90.10, 90.15, 90.20, 90.25, 90.30, 90.35, 90.40, 90.45, 90.50, 90.55, 90.60, 90.65, 90.70, 90.75, 90.80, 90.85, 90.90, 90.95, 91.00, 91.05, 91.10, 91.15, 91.20, 91.25, 91.30, 91.35, 91.40, 91.45, 91.50, 91.55, 91.60, 91.65, 91.70, 91.75, 91.80, 91.85, 91.90, 91.95, 92.00, 92.05, 92.10, 92.15, 92.20, 92.25, 92.30, 92.35, 92.40, 92.45 92.50, 92.55, 92.60, 92.65, 92.70, 92.75, 92.80, 92.85, 92.90, 92.95, 93.00, 93.05, 93.10, 93.15, 93.20, 93.25, 93.30, 93.35, 93.40, 93.45, 93.50, 93.55, 93.60, 93.65, 93.70, 93.75, 93.80 93.85, 93.90, 93.95, 94.00, 94.05, 94.10, 94.15, 94.20, 94.25, 94.30, 94.35, 94.40, 94.45, 94.50, 94.55, 94.60, 94.65, 94.70, 94.75, 94.80, 94.85, 94.90, 94.95, 95.00% mass, or a range defined by any two of these.

[0104] In an embodiment, the nutritional composition comprises 0.5-6% by weight, for example 1-3% by weight, of γ-aminobutyric acid (GABA), such as 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 1.05, 1.10, 1.15, 1.20, 1.25, 1.30, 1.35, 1.40, 1.45, 1.50, 1.5 5, 1.60, 1.65, 1.70, 1.75, 1.80, 1.85, 1.90, 1.95, 2.00, 2.05, 2.10, 2.15, 2.20, 2.25, 2.30, 2.35, 2.40, 2.45, 2.50, 2.55, 2.60, 2.65, 2.70, 2.75, 2.80, 2.85, 2.90, 2.95, 3.00, 3.05 3.10, 3.15, 3.20, 3.25, 3.30, 3.35, 3.40, 3.45, 3.50, 3.55, 3.60, 3.65, 3.70, 3.75, 3.80, 3.85, 3.90, 3.95, 4.05, 4.10, 4.15, 4.20, 4.25, 4.30, 4.35, 4.40, 4.45, 4.50, 4.55, 4.60, 4 65, 4.70, 4.75, 4.80, 4.85, 4.90, 4.95, 5.05, 5.10, 5.15, 5.20, 5.25, 5.30, 5.35, 5.40, 5.45, 5.50, 5.55, 5.60, 5.65, 5.70, 5.75, 5.80, 5.85, 5.90, 5.95, 6.00% mass, or a range defined by any two of these.

[0105] In an embodiment, the nutritional composition comprises 0.5-6% by weight, for example 1-3% by weight, of L-theanine, such as 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 1.05, 1.10, 1.15, 1.20, 1.25, 1.30, 1.35, 1.40, 1.45, 1.50, 1.55%. 1.60, 1.65, 1.70, 1.75, 1.80, 1.85, 1.90, 1.95, 2.00, 2.05, 2.10, 2.15, 2.20, 2.25, 2.30, 2.35, 2.40, 2.45, 2.50, 2.55, 2.60, 2.65, 2.70, 2.75, 2.80, 2.85, 2.90, 2.95, 3.00, 3.05 3.10, 3.15, 3.20, 3.25, 3.30, 3.35, 3.40, 3.45, 3.50, 3.55, 3.60, 3.65, 3.70, 3.75, 3.80, 3.85, 3.90, 3.95, 4.05, 4.10, 4.15, 4.20, 4.25, 4.30, 4.35, 4.40, 4.45, 4.50, 4.55, 4.60, 4 65, 4.70, 4.75, 4.80, 4.85, 4.90, 4.95, 5.05, 5.10, 5.15, 5.20, 5.25, 5.30, 5.35, 5.40, 5.45, 5.50, 5.55, 5.60, 5.65, 5.70, 5.75, 5.80, 5.85, 5.90, 5.95, 6.00% mass, or a range defined by any two of these.

[0106] In this embodiment, the nutritional composition includes sodium carboxymethyl cellulose; compared to not using sodium carboxymethyl cellulose or using other stabilizers such as sodium alginate, the prepared nutritional composition exhibits significantly improved solution stability after brewing. Sodium carboxymethyl cellulose may be, for example, 0.5-4% by mass relative to the total mass of the nutritional composition, such as 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 1.05, 1.10, 1.15, 1.20, 1.25, 1.30, 1.35, 1.40, 1.45, 1.50, 1.55, 1.60, 1.65, 1.70, 1.75, 1.80, 1.85, 1.90, 1.95, 2.00, 2.05, 2.10, 2.15. 2.20, 2.25, 2.30, 2.35, 2.40, 2.45, 2.50, 2.55, 2.60, 2.65, 2.70, 2.75, 2.80, 2.85, 2.90, 2.95, 3.00, 3.00, 3.05, 3.10, 3.15, 3.20, 3.25, 3.30, 3.35, 3.40, 3.45, 3.50, 3.55, 3.60, 3.65, 3.70, 3.75, 3.80, 3.85, 3.90, 3.95, 4.00% mass, or a range defined by any two of these.

[0107] The number-average molecular weight of the sodium carboxymethyl cellulose is not particularly limited and can be any molecular weight commonly used in the art, for example, 30,000 to 1,000,000, such as 30,000, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000,000 or any range defined by both of these.

[0108] In an embodiment, the nutritional composition comprises 0.05-1.0% by weight of silica, such as 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00% by weight, or a range defined by any two thereof.

[0109] The silica may be, for example, fumed silica, precipitated silica, or a mixture thereof.

[0110] In this embodiment, the primary particle size (particle size of primary particles) of silica is not particularly limited and is typically 5-100 nanometers, for example, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 nanometers or a range defined by any two thereof. In this application, particle size refers to the Dv50 particle size, i.e., a particle size in which 50% of the volume of particles in its cumulative volume distribution curve has a particle size lower than this size, and 50% of the volume of particles has a particle size higher than this size.

[0111] In this embodiment, the specific surface area of ​​silica (e.g., determined by the BET nitrogen adsorption method) is not particularly limited and is typically 10-500 m². 2 / g, for example, can be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500m 2 / g or the range defined by either / g or either of them.

[0112] In an embodiment, the nutritional composition comprises 0.01-1.0% by weight of milk protein peptides, such as 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00% by weight, or a range defined by any two thereof.

[0113] In this application, the term "milk protein peptide" refers to all peptides produced from proteins (i.e., milk proteins) in animal milk (mainly cow's milk, but also including goat's milk, etc.) through enzymatic hydrolysis, fermentation, or other controlled degradation methods.

[0114] In the embodiments, the milk protein peptides used in this application can be powdered products made from raw milk through processes such as filtration, sterilization, defatting and separation of most of the whey, followed by enzymatic hydrolysis, enzyme inactivation, concentration and drying.

[0115] For example, in this application, the milk protein peptides may be milk protein peptides in which peptides with a relative molecular mass of less than 10,000 Da account for about 60%.

[0116] In an embodiment, the nutritional composition comprises 0.01-1.0% by weight of colostrum peptide powder, such as 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00% by weight, or a range defined by any two thereof.

[0117] In this embodiment, the colostrum peptide powder may be, for example, bovine colostrum peptide powder, sheep colostrum peptide powder, or a mixture thereof.

[0118] In this embodiment, the colostrum peptide powder may be prepared, for example, by a low-temperature process or enzymatic hydrolysis.

[0119] In an embodiment, the nutritional composition comprises 0.05-1.0% by weight of a compound plant extract, such as 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00% by weight, or a range defined by any two thereof.

[0120] In this embodiment, the compound plant extract is not particularly limited and may include, for example, two or more of the following: tea theanine, lily powder, passion fruit powder, jujube seed powder, and saffron extract, preferably including or comprising tea theanine, lily powder, passion fruit powder, jujube seed powder, and saffron extract; preferably, relative to 1 part by weight of lily powder, tea theanine may be, for example, 0.5-4.0 parts by weight, preferably 1.0-2.0 parts by weight, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, etc. 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0 parts by weight, or a range defined by any two thereof; passion fruit powder may be, for example, 0.5-2.0 parts by weight, preferably 0.5-1.0 parts by weight, such as 0.5, 0.6, 0. 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0 parts by weight, or any range thereof; jujube seed powder may be, for example, 0.5-2.0 parts by weight, preferably 0.5-1.5 parts by weight, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0 parts by weight, or any range thereof. The ranges defined by both are as follows: saffron extract may be, for example, 0.05-1.0 parts by weight, preferably 0.1-0.5 parts by weight, such as 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 parts by weight, or the ranges defined by any two thereof; more preferably, the mass ratio of tea theanine: lily powder: passionflower powder: jujube seed powder: saffron extract is 1.6:1:0.8:1:0.2. Those skilled in the art will understand that the amounts and ratios mentioned above are based solely on the corresponding plant extract components and do not include excipients such as maltodextrin added during processing after the raw material extraction.

[0121] In this embodiment, the nutritional composition includes a sweetener selected from steviol glycosides and / or mogrosides; the nutritional composition has an improved taste (dry powder aroma and brewed aroma) compared to the absence of a sweetener. The steviol glycosides and / or mogrosides may be 0.01-1.0% by mass relative to the total mass of the nutritional composition, for example, 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00% by mass, or a range defined by any two thereof. Preferably, the sweetener is steviol glycoside, or a combination of steviol glycoside and mogroside, more preferably steviol glycoside; compared to the case where the sweetener is mogroside, the prepared nutritional composition has an improved taste (dry powder aroma and brewed aroma).

[0122] In some embodiments, the mass ratio of γ-aminobutyric acid (GABA) to L-theanine is 6:1 to 1:6, for example, 6:1, 5:1, 4:1, 3:1, 2:1, 1.5:1, 1.2:1, 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:6, or a range defined by any two thereof. Preferably, the mass ratio of GABA to L-theanine is 3:1 to 1:3, more preferably 3:1 to 1:1, and even more preferably 1:1. Within these preferred ranges, the nutritional composition can significantly improve sleep compared to ratios outside the range.

[0123] In a preferred embodiment, the nutritional composition comprises:

[0124] 93-94% quality emulsion base powder,

[0125] 1.9-2.1% by mass of γ-aminobutyric acid,

[0126] 1.9-2.1% L-theanine by mass

[0127] 1.4-1.6% sodium carboxymethyl cellulose by weight

[0128] 0.15-0.25% silica by mass

[0129] 0.05-0.15% by weight of milk protein peptides,

[0130] 0.05-0.15% colostrum peptide powder by weight,

[0131] 0.10-0.20% by weight of compound plant extracts,

[0132] 0.05-0.15% by weight of steviol glycosides.

[0133] When the nutritional composition has the above-mentioned preferred composition, compared with other compositions outside the preferred range, the nutritional composition has, on the one hand, further improved solution stability after brewing and improved taste (dry powder aroma and brewed aroma), and on the other hand, further improved sleep-improving efficacy.

[0134] Preparation method of nutritional composition

[0135] In a second aspect, the present invention relates to a method for preparing a nutritional composition according to the first aspect of the present invention, comprising the following steps:

[0136] (1) Ingredients: Provide the formula amount of milk base powder, γ-aminobutyric acid, L-theanine, sodium carboxymethyl cellulose, silicon dioxide, milk protein peptides, colostrum peptide powder, compound plant extracts and sweeteners;

[0137] (2) Premixed:

[0138] (2-1) Disperse and granulate the formulated amounts of silica, milk protein peptides, colostrum peptide powder, compound plant extracts, and sweeteners to obtain premix A; and

[0139] (2-2) Disperse and granulate the formulated amounts of γ-aminobutyric acid and L-theanine to obtain premix B;

[0140] (3) Sieving: The emulsion base powder, premix A, premix B, and sodium carboxymethyl cellulose are passed through a vibrating screen in n batches. The resulting materials enter the mixing drum.

[0141] - n is a positive integer of 3 or greater.

[0142] - Sodium carboxymethyl cellulose is added in the i-th batch, where i is a positive integer ≤ n / 2;

[0143] - In each of batches 1 to n-2, when sodium carboxymethyl cellulose is not present, the ingredients are added in the order of 1 / n formula amount of emulsion powder, 1 / n formula amount of premix A, and 1 / n formula amount of premix B; and when sodium carboxymethyl cellulose is present, the ingredients are added in the order of 1 / n formula amount of emulsion powder, 1 / n formula amount of premix A, 1 / n formula amount of premix B, and formula amount of sodium carboxymethyl cellulose.

[0144] -In the n-1th batch, the emulsion base powder (1 / 2n of the formula amount), premix A (1 / n of the formula amount), and premix B (1 / n of the formula amount) are added in that order;

[0145] -In the nth batch, the ingredients are added in the following order: 1 / 2n of the formula amount of emulsion base powder, 1 / n of the formula amount of premix A, 1 / n of the formula amount of premix B, and 1 / n of the formula amount of emulsion base powder.

[0146] (4) Dry mixing: The materials obtained in the mixing cylinder in step (3) are dry mixed to obtain the nutritional composition.

[0147] All descriptions above relating to the first aspect of the present invention are applicable here and will not be repeated here.

[0148] In one embodiment, the method includes premixing; compared to the case where no premixing is performed, the components in the prepared nutritional composition are mixed more uniformly, i.e., have a more uniform composition.

[0149] In the implementation, in steps (2-1) and (2-2), dispersion can be carried out independently by any means known in the art (e.g., stirring).

[0150] In this application, the term "granulation" has a meaning known in the art, referring to the process of reducing mechanical damage to particles and avoiding excessive crushing by controlling process parameters (such as rotation speed, pressure, and temperature) during mixing, conveying, or subsequent processing after raw material premixing, thereby maintaining or restoring the integrity of the particles and preserving their original or near-original particle structure, so that the final product retains clearly visible intact particles or larger particle shapes. Therefore, the term "granulation" is different from "crushing" (actively reducing particle size) and "granulation" (re-aggregating powder into artificial particles).

[0151] In this implementation, the granulation in steps (2-1) and (2-2) can be carried out independently by a granulator.

[0152] In the implementation, the granulation in steps (2-1) and (2-2) can be performed at the same or different, preferably the same, operating frequencies, and the operating frequencies can each be independently 10-60 Hz, for example 30-35 Hz, such as 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 Hz, or a range defined by any two of them.

[0153] In the implementation, the granulation in steps (2-1) and (2-2) may each use the same or different, preferably the same, sieves and the sieves may each be independently 10-60 mesh, for example 20-40 mesh, for example 10, 20, 30, 40, 50, 60 mesh, or a range defined by any two of them.

[0154] In the embodiment, in the sieving step (3), the milk base powder, premix A, premix B and sodium carboxymethyl cellulose are passed through a vibrating sieve in n batches; when n is 3 or a larger positive integer, the components in the prepared nutritional composition are mixed more evenly, i.e., have a more uniform composition, compared to the case where the milk base powder, premix A, premix B and sodium carboxymethyl cellulose are passed through the vibrating sieve in fewer batches (i.e., n is 1 or 2).

[0155] In one embodiment, n=3, and in step (3), the emulsion base powder, premix A, premix B, and sodium carboxymethyl cellulose are added in the following order:

[0156] Batch 1: 1 / 3 of the formula amount of emulsion base powder, 1 / 3 of the formula amount of premix A, 1 / 3 of the formula amount of premix B, and the formula amount of sodium carboxymethyl cellulose.

[0157] Batch 2: 1 / 6 of the formula amount of emulsion base powder, 1 / 3 of the formula amount of premix A, and 1 / 3 of the formula amount of premix B.

[0158] Batch 3: 1 / 6 of the formula amount of emulsion base powder, 1 / 3 of the formula amount of premix A, 1 / 3 of the formula amount of premix B, and 1 / 3 of the formula amount of emulsion base powder.

[0159] In one embodiment, n=4, and in step (3), the emulsion base powder, premix A, premix B, and sodium carboxymethyl cellulose are added in the following order:

[0160] Batch 1: 1 / 4 of the formula amount of base material, 1 / 4 of the formula amount of premix A, and 1 / 4 of the formula amount of premix B.

[0161] Batch 2: 1 / 4 of the formula amount of base material, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, and sodium carboxymethyl cellulose.

[0162] Batch 3: 1 / 8 of the formula amount of base material, 1 / 4 of the formula amount of premix A, and 1 / 4 of the formula amount of premix B.

[0163] Batch 4: 1 / 8 of the formula amount of base material, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, and 1 / 4 of the formula amount of base material.

[0164] When n is 4, compared to when n is 3, the components in the prepared nutritional composition are mixed more evenly, that is, they have a more uniform composition.

[0165] In an implementation, the vibrating screen used in step (3) may be, for example, 10-30 mesh, such as 10, 20, 30 mesh, or a range defined by any two of them.

[0166] In an embodiment, the dry mixing in step (4) may be performed, for example, by stirring. The dry mixing / stirring may be performed, for example, at a low speed, such as 5-60 rpm (e.g., 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 rpm or a range defined by any two thereof).

[0167] The nutritional composition prepared by the method of the present invention has a more uniform composition than nutritional compositions prepared by other methods, with the components mixed more evenly.

[0168] Therefore, the present invention also relates to nutritional compositions prepared by the preparation method according to the second aspect of the present invention. All descriptions above relating to the first and second aspects of the present invention are applicable here and will not be repeated here.

[0169] Uses of nutritional compositions

[0170] In a third aspect, the present invention also relates to the use of a nutritional composition according to the first aspect of the invention or a nutritional composition prepared by the preparation method according to the second aspect of the invention in improving sleep, or in the preparation of a product for improving sleep.

[0171] All descriptions above relating to the first and second aspects of the present invention are applicable here and will not be repeated here.

[0172] In this implementation, the use is for non-therapeutic purposes, i.e., for nutritional and / or health purposes.

[0173] In some implementations, the subjects for whom sleep improvement is sought are not particularly limited and may include, for example, teenagers, adults, young adults, middle-aged people, and / or the elderly.

[0174] In some embodiments, the nutritional composition is intended for oral administration to humans.

[0175] In some embodiments, when the nutritional composition is taken orally in humans, the recommended daily dose may be appropriately selected depending on the intended use (e.g., the target population) and is typically, for example, 10-100 g / day, such as 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 g / day, or a range defined by any two thereof.

[0176] Experimental Example

[0177] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to experimental examples. It should be understood that the specific experimental examples described herein are merely illustrative and not intended to limit the invention. Unless otherwise specified, the reagents, methods, and equipment used in this invention are conventional in the art.

[0178] 1. Experimental Materials

[0179] Casein Powder: Brand: Leprino Foods Dairy Products Company; Specifications: Protein ≥ 86g / 100g, Casein (as a percentage of total protein) ≥ 82g / 100g; This batch of samples tested showed a protein content of 89.5g / 100g, and the casein test result was "meets specifications"; Sample Batch Number: 2023.09.06

[0180] Gamma-aminobutyric acid (GABA): Brand: Bloomage Biotechnology Co., Ltd.; Specification: GABA ≥98% by weight; the test result of this batch of samples is 98.16% by weight.

[0181] L-Theanine: Brand: Shaanxi Jiahe Pharmaceutical Co., Ltd.; Specification: L-Theanine approximately 98%; This batch of samples, according to HPLC testing, has a purity of 98.16%.

[0182] Sodium carboxymethyl cellulose: Brand: Hebi Fangrui Chemical Products Co., Ltd.; Specification: Sodium carboxymethyl cellulose ≥99.5% purity; Product model: FH9 acid resistant; This batch of samples, tested according to GB 1886.232-2016 Annex A.3, yielded a purity of 99.72% purity.

[0183] Sodium alginate: Brand: Qingdao Mingyue Seaweed Group Co., Ltd., Specification: Food additive, Batch number: JTYPSQ20240719224

[0184] Silica: Brand: Qingdao Evonik Silica Materials Co., Ltd., Precipitation method carbon dioxide, Specification: ≥96% silica by weight, Product Model: SIPERNAT® 22 SF, This batch of samples, based on the test results after ignition, is 98.2% by weight.

[0185] Milk protein peptides: Brand: Heilongjiang Feihe Dairy Co., Ltd.; Specifications: Peptides with a relative molecular mass of less than 10,000 Da account for approximately 60%.

[0186] Colostrum peptide powder: Brand: Feihe (Baiquan) Dairy Co., Ltd., Specification: Protein ≥68g / 100g, Batch number: 4H08QB1600, Batch test result: 89% quality;

[0187] The compound plant extract is composed of the following raw materials: tea theanine (brand: Shanghai Nord Biotechnology Co., Ltd., composition: 60-80% tea theanine, 20-40% maltodextrin), lily powder (brand: Shandong Lvyou Food Technology Co., Ltd.), passion fruit powder (brand: Tianjin Tangchao Food Industry Co., Ltd., composition: 80% passion fruit juice, 20% maltodextrin), jujube seed powder (brand: Shaanxi Jiahe Pharmaceutical Co., Ltd., specification: total saponins ≥2.0% by mass), and saffron extract (brand: Satiereal, specification: saffron aldehyde ≥0.34% by mass). The mass ratio of tea theanine: lily powder: passion fruit powder: jujube seed powder: saffron extract in the compound plant extract is 1.6:1:0.8:1:0.2.

[0188] Steviosides: Brand: Shandong Aojing Biotechnology Co., Ltd.; Specification: Rebaudioside A content ≥98% by weight. This batch of samples, according to GB 1886.355-2022 A.3, has a quality of 98.67% by weight.

[0189] Monk fruit glycosides: Brand: Guilin Jifusi Monk Fruit Biotechnology Co., Ltd.; Specifications: Monk fruit glycoside content 48%–52% by weight; Model: MFC-E50; This batch's test result is 50.12% by weight.

[0190] In the following embodiments, unless otherwise specified, when referring to the amount of γ-aminobutyric acid, L-theanine, sodium carboxymethyl cellulose, compound plant extracts, steviol glycosides, mogrosides, casein powder, sodium alginate, silica, milk protein peptides, and colostrum peptide powder, it refers to the amount of the raw materials used.

[0191] Example 1

[0192] Composition 1 was prepared as follows:

[0193] (1) Ingredients: Accurately weigh 93.75 parts of milk protein powder, 2 parts of γ-aminobutyric acid, 2 parts of L-theanine, 1.5 parts of sodium carboxymethyl cellulose, 0.2 parts of silicon dioxide, 0.1 parts of milk protein peptide, 0.1 parts of colostrum peptide powder, 0.2 parts of compound plant extract and 0.15 parts of steviol glycoside;

[0194] (2) Premixed:

[0195] (2-1) Disperse the silica, milk protein peptides, colostrum peptide powder, compound plant extracts and steviol glycosides in the formula amount, and then pass them through a 30-mesh sieve and a high-speed granulator (30-35Hz) to obtain premix A;

[0196] (2-2) Disperse the γ-aminobutyric acid and L-theanine in the formula, pass them through a 30-mesh sieve and a high-speed granulator (30-35Hz) to obtain premix B;

[0197] (3) Sieving:

[0198] The milk protein powder, premix A, premix B, and sodium carboxymethyl cellulose were divided into four batches and passed through a 20-mesh vibrating sieve in the following order: 1 / 4 of the formula amount of milk protein powder, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, 1 / 4 of the formula amount of milk protein powder, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, 1 / 8 of the formula amount of milk protein powder, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, 1 / 8 of the formula amount of milk protein powder, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, and 1 / 4 of the formula amount of milk protein powder. The materials were then fed into a mixing tank.

[0199] (4) Dry mixing: Mix the materials in the mixing tank of step (3) at 10 rpm for 30 minutes to obtain composition 1.

[0200] Stability test:

[0201] The stability of composition 1 was tested as follows: 10 g of composition 1 was added to 100 mL of warm water (approximately 50°C) and stirred thoroughly to dissolve. Then, it was added to a test tube (LUM cell) and centrifuged at 3000 rpm at a set temperature of 25°C. o Centrifuge at C for 2 hours. With the acceleration of centrifugation, unstable samples may precipitate, suspend, or solidify. Stability is evaluated by using the LUMiSizer 611 to test the dynamic change in transmittance (also known as light transmittance) of the sample from the start to the end of centrifugation. The LUMiSizer 611 is an instrument that uses centrifugal force to accelerate the separation process and combines it with a near-infrared optical detection system to rapidly and quantitatively analyze the stability of a dispersion system. It uses near-infrared light as the light source, illuminating the entire spatial range of the sample in parallel, and uses an optical sensor CCD to detect transmittance to obtain spatial and temporal extinction spectra.

[0202] Figure 1 This image shows the dynamic change in transmittance of sample composition 1 during centrifugation. It reflects the transmittance data measured every 5 minutes. The images are arranged from the bottom first line upwards to represent the 0th 5-minute interval, the 1st 5-minute interval, the 2nd 5-minute interval, and so on, until the end of the 2-hour test. Figure 2 This image shows the state of composition 1 sample after stability testing.

[0203] Depend on Figure 1 and 2As can be seen, with the acceleration of centrifugation, the transmittance of the middle part of the sample in Example 1 increased, while the upper and lower parts were relatively low, with no obvious stratification. The clarity index generated and displayed by the instrument after testing was 0.054. (Note: The more severe the solution stratification, the higher the clarity index.)

[0204] Taste test:

[0205] Taste testing was conducted on composition 1. A team of 10 expert evaluators was recruited to test the aroma of the dry powder and the aroma of the emulsion after dissolving (10g of composition dissolved in 100mL of warm water). A 5-point scoring method was used, and the test results are shown in Table 1 below:

[0206] Table 1

[0207]

[0208] Based on the taste test results, the evaluators gave the average score of 3.9 / 5 for both the aroma of the dry powder and the aroma of the emulsion after brewing, indicating good acceptance.

[0209] Mixing uniformity:

[0210] After dry mixing, two random samples were taken from the upper part of the mixing tank, one from the middle part, and two from the lower part. The uniformity of the color of the mixed material was observed. The theanine content in the samples was determined according to GB / T 23193, and the relative standard deviation (RSD) of the results was calculated. An RSD ≤ 5 was considered a uniformly mixed sample, and an RSD ≥ 5 was considered an unevenly mixed sample.

[0211] Based on the test results, the test results and RSD calculation values ​​for each sampling point in Example 1 are shown in Table 2 below:

[0212] Table 2

[0213]

[0214] The results showed that the composition in Example 1 was uniformly mixed.

[0215] Example 2

[0216] Composition 2 was prepared in the same manner as in Example 1, except that in the formulation step (1), the amount of γ-aminobutyric acid was changed to 3 parts and the amount of L-theanine was changed to 1 part.

[0217] Example 3

[0218] Composition 3 was prepared in the same manner as in Example 1, except that in the formulation step (1), the amount of γ-aminobutyric acid was changed to 1 part and the amount of L-theanine was changed to 3 parts.

[0219] Example 4

[0220] Composition 4 was prepared in the same manner as in Example 1, except that in step (3), the milk protein powder, premix A, premix B and sodium carboxymethyl cellulose were passed through a 20-mesh vibrating sieve in three batches in the following order: 1 / 3 of the formula amount of milk protein powder, 1 / 3 of the formula amount of premix A, 1 / 3 of the formula amount of premix B, the formula amount of sodium carboxymethyl cellulose, 1 / 6 of the formula amount of milk protein powder, 1 / 3 of the formula amount of premix A, 1 / 3 of the formula amount of premix B, 1 / 6 of the formula amount of milk protein powder, 1 / 3 of the formula amount of premix A, 1 / 3 of the formula amount of premix B, and 1 / 3 of the formula amount of milk protein powder.

[0221] Mixing uniformity:

[0222] The mixing uniformity of composition 4 was tested in the same manner as in Example 1.

[0223] Based on the test results, the test results and RSD calculation values ​​of each sampling point in Example 4 are shown in Table 3 below:

[0224] Table 3

[0225]

[0226] The results showed that the composition in Example 4 was uniformly mixed.

[0227] Example 5

[0228] Composition 5 was prepared in the same manner as in Example 1, except that in the formulation step (1), 0.15 parts of steviol glycosides were replaced with 0.15 parts of mogrosides.

[0229] Taste test:

[0230] The taste of composition 5 was tested in the same manner as in Example 1. The test results are shown in Table 4 below:

[0231] Table 4

[0232]

[0233] Based on the taste test results, the average score of the dry powder aroma of the composition was 3.7 / 5, and the average score of the emulsion aroma after brewing was 3.4 / 5. The acceptance level was good, but slightly lower than the taste test results of Example 1.

[0234] Comparative Example 1

[0235] Comparative composition 1 was prepared in the same manner as in Example 1, except that in the formulation step (1), 1.5 parts of sodium carboxymethyl cellulose were replaced with 1.5 parts of sodium alginate.

[0236] Stability test:

[0237] The stability of the control composition 1 was tested in the same manner as in Example 1.

[0238] Figure 3 This shows the dynamic change in transmittance of the comparative composition 1 sample during centrifugation. Figure 4 Images showing the state of Comparative Composition 1 sample after stability testing.

[0239] Depend on Figure 3 and 4 As can be seen, with the acceleration of centrifugation, the transmittance of the middle part of the sample in Comparative Example 1 increases, while the upper and lower parts are relatively low, showing obvious stratification. The clarification index generated by the instrument after testing was 0.034. Meanwhile, swollen crystals were found floating on the surface of the solution after preparation.

[0240] Comparative Example 2

[0241] Comparative composition 2 was prepared in the same manner as in Example 1, except that sodium carboxymethyl cellulose was not used in the formulation step (1) and the amount of milk protein powder was changed from 93.25 parts to 95.25 parts.

[0242] Stability test:

[0243] The stability of the control composition 2 was tested in the same manner as in Example 1.

[0244] Figure 5 This shows the dynamic change in transmittance of the comparative composition 2 sample during centrifugation. Figure 6 Images showing the state of Comparative Composition 2 sample after stability testing.

[0245] Depend on Figure 5 and 6 As can be seen, with the acceleration of centrifugation, the transmittance of the middle part of the Comparative Example 2 sample increased, while the upper and lower parts were relatively low, with no obvious stratification. The clarification index generated by the instrument after testing was 0.099. Meanwhile, after preparing the solution and letting it stand for a short time, a large amount of plant extract powder precipitated at the bottom, indicating poor product stability.

[0246] Comparative Example 3

[0247] Comparative composition 3 was prepared in the same manner as in Example 1, except that: no steviol glycosides were added in the formulation step (1) and the amount of milk protein powder was changed from 93.25 parts to 93.9 parts.

[0248] Taste test:

[0249] The taste of comparative composition 3 was tested using the same method as in Example 1. The test results are shown in Table 5 below:

[0250] Table 5

[0251]

[0252] Based on the taste test results, the evaluators gave the composition powder an average score of 2.5 / 5 for odor and the emulsion after brewing an average score of 2.0 / 5 for odor, indicating poor acceptance and a much lower score than the taste test results of Examples 1 and 5.

[0253] Comparative Example 4

[0254] Comparative composition 4 was prepared in the same manner as in Example 1, except that: premixing step (2) was not performed and in step (3) the formulated amounts of milk protein powder, silica, milk protein peptide, colostrum peptide powder, compound plant extract, steviol glycoside, sodium carboxymethyl cellulose, γ-aminobutyric acid, and L-theanine were sequentially passed through a 20-mesh vibrating sieve.

[0255] Mixing uniformity:

[0256] The mixing uniformity of the comparative composition 4 was evaluated in the same manner as in Example 1. The results are shown in Table 6 below:

[0257] Table 6

[0258]

[0259] The results showed that the composition in Comparative Example 4 did not meet the requirements for uniform mixing.

[0260] Comparative Example 5

[0261] Comparative composition 5 was prepared in the same manner as in the examples, except that in step (3), the milk protein powder, sodium carboxymethyl cellulose, premix A, and premix B were passed through a 20-mesh vibrating sieve in sequence.

[0262] Mixing uniformity:

[0263] The mixing uniformity of the comparative composition 5 was evaluated in the same manner as in Example 1, and the results are shown in Table 7 below:

[0264] Table 7

[0265]

[0266] The results showed that the composition in Comparative Example 5 did not meet the requirements for uniform mixing.

[0267] Comparative Example 6

[0268] Comparative composition 6 was prepared in the same manner as in Example 1, except that in step (3), the milk protein powder, premix A, premix B and sodium carboxymethyl cellulose were passed through a 20-mesh vibrating sieve in two batches in the following order (1 / 2 formula amount of milk protein powder, 1 / 2 formula amount of premix A, 1 / 2 formula amount of premix B, formula amount of sodium carboxymethyl cellulose, 1 / 4 formula amount of milk protein powder, 1 / 2 formula amount of premix A, 1 / 2 formula amount of premix B, 1 / 4 formula amount of milk protein powder).

[0269] Mixing uniformity:

[0270] The mixing uniformity of the comparative composition 6 was evaluated in the same manner as in Example 1, and the results are shown in Table 8 below:

[0271] Table 8

[0272]

[0273] The results showed that the composition in Comparative Example 6 did not meet the requirements for uniform mixing.

[0274] Evaluation Example 1: Animal Experiment on Sleep-Promoting Efficacy

[0275] 1. Laboratory animals

[0276] Wild-type AB strain zebrafish were used, with a fish age of 5 days post-fertilization (5 dpf). Each experimental group had a sample size of 30 fish (three biological replicates, N=3). All zebrafish were reared in aquarium water at 28°C (water quality: 200 mg of readily soluble sea salt added per 1 L of reverse osmosis water; conductivity 450–550 μS / cm; pH 6.5–8.5; hardness 50–100 mg / L CaCO3).

[0277] 2. Modeling methods and principles

[0278] A pentylenetetrazole (PTZ)-induced insomnia model in zebrafish. Based on the genetic and neuroanatomical similarities between zebrafish and humans, their sleep cycles are also very similar. Zebrafish exhibit a remarkably similar circadian rhythm to humans, displaying a diurnal activity pattern. Adult zebrafish are highly active during the day with short periods of inactivity, and the opposite at night. Typically, inactive zebrafish will droop their tail fins, a state resembling sleep. Zebrafish larvae show a distinct circadian rhythm at 4-8 days post-flood (dpf), and larvae and adults exhibit remarkably similar neuronal response patterns. Furthermore, zebrafish sleep is easily influenced by external stimuli such as light, temperature, and sound, and their melatonin levels also show a circadian rhythm, very similar to that in humans. Gamma-aminobutyric acid (GABA) is a naturally occurring non-protein amino acid and an important inhibitory neurotransmitter in the mammalian central nervous system; PTZ is an inhibitor of GABA. Low-dose PTZ can induce bipolar disorder in zebrafish, exhibiting both mania and depression, thus causing insomnia. Nervous tension can lead to insomnia, and prolonged insomnia, in turn, further exacerbates nervous tension, creating a vicious cycle. Improving neurotransmitters and supplementing neurotrophic factors can help reduce the excitability and stress response of the nervous system, thus soothing the nerves and achieving relaxation and alleviating insomnia. Furthermore, in a state of insomnia, the transmission of neurotransmitters between neurons, synapses, and axons is also disrupted. Low-dose PTZ can increase neuronal excitability, leading to excessive neuronal discharge. This excessive discharge may lead to increased local metabolic demand, resulting in insufficient energy supply and oxidative stress, causing axonal damage.

[0279] 3. Instruments, consumables and reagents

[0280] 3.1 Instruments

[0281] Artificial climate incubator (RGX-70ES, Shanghai Rongjida Instrument Technology Co., Ltd.), quantitative PCR instrument (Q1000REAL-TIME, Hangzhou Bori Technology Co., Ltd.), high-speed refrigerated centrifuge (LC-LX-HR165A, Hunan Xiangyi Laboratory Instrument Development Co., Ltd.), zebrafish behavior analysis system (Viewpoint ZebraBox, Viewpoint France).

[0282] 3.2 Consumables and Reagents

[0283] 90 mm culture dishes, 60 mm culture dishes, 3 mL plastic droppers, 1.5 mL EP tubes, 15 mL EP tubes, 50 mL EP tubes, etc. (all consumables were purchased from Lanjieke Biotechnology Co., Ltd.)

[0284] 60×E3 solution (NaCl2 17.4g / L; CaCl2•2H2O 2.9g / L; KCl 0.8g / L; MgCl2•6H2O 4.89g / L, Suzhou Murui Biotechnology Co., Ltd.), DMSO (≥99.9%, CAS: 67-68-5, Sinopharm Chemical Reagent Co., Ltd.), Methylene blue (≥98%, CAS: 7220-79-3, Shanghai Aladdin Biochemical Technology Co., Ltd.), Pentyltetrazole (PTZ, ≥99%, Sigma-Aldrich, USA), Animal tissue / cell total RNA rapid extraction kit (ZOMANBIO ZP404, Zhuangmeng Biotechnology), Zhuangmeng first-strand reverse transcription kit (ZOMANBIO ZR102, Zhuangmeng Biotechnology), 2×SYBR Kit (Hefei Bomei Biotechnology Co., Ltd.), Zebrafish GABA content detection ELISA kit (Shanghai Huabang Biotechnology Co., Ltd.), Melatonin (commercially available health food, By-Health Co., Ltd.).

[0285] 4. Experimental Procedure

[0286] 4.1 Determination of Maximum Detectable Concentration (MTC)

[0287] Six groups were set up, including a control group and a sample group (with five concentration gradients: 1 μg / mL, 10 μg / mL, 100 μg / mL, 500 μg / mL, and 1000 μg / mL). Zebrafish 5 days post-fertilization (5 dpf) were exposed to samples in a six-well plate (5 mL / well), with 10 fish per well. After 96 hours of treatment, the mortality rate, heart rate, and deformity rate of the zebrafish were observed to determine the maximum treatment concentration of the samples.

[0288] 4.2 Behavioral Testing

[0289] Six groups were set up, including a control group, a model group (modeled using 3 mM PTZ according to literature data, reference: Ellis LD, Soanes KH. A larval zebrafish model of bipolar disorder as a screening platform for neuro-therapeutics[J]. Behav Brain Res. 2012, 233(2):450-457.), a positive drug group (melatonin, with a concentration of 5 μM according to literature data, reference: Zhdanova IV, Wang SY, Leclair OU, et al. Melatonin promotes sleep-like state in zebrafish[J]. Brain Research, 2001, 903(1-2):263-268.), and a sample group (compositions 1, 2, and 3, with the same concentration set according to the results in 4.1). Zebrafish with a uniform growth rate of 5 dpf were randomly selected into 6-well plates, with 10 fish per well and 3 replicates per group. The control group was cultured normally under standard conditions. The model group was induced using 3 mM PTZ. The positive drug group was treated with 5 μM melatonin and 3 mM PTZ. The sample group was treated with 3 mM PTZ and intervened using one concentration of sample. After 24 h of culture, 5 fish from each group were randomly selected into 48-well plates, one fish per well. The autonomous behavior of each group was monitored for 30 min using a zebrafish behavior tracking system.

[0290] 4.3 Detection of relative expression levels of GABA-A receptor gene

[0291] After the behavioral tests were completed, five juvenile fish from each culture dish were quickly collected into pre-cooled RNase-free centrifuge tubes, with each centrifuge tube corresponding to a group of juvenile fish. Total RNA was extracted from the zebrafish, reverse transcribed to obtain cDNA products, and then detected by real-time quantitative PCR. The relative expression level of the GABA-A receptor gene was statistically analyzed.

[0292] 4.4 GABA Content Detection

[0293] After behavioral testing, five juvenile fish from each culture dish were quickly subjected to cell disruption and centrifugation. The supernatant was then diluted 1:5 (100 μL supernatant + 400 μL kit sample dilution). The samples were added to the wells and incubated at 37°C. The fish were then washed with 0.05% PBST buffer (containing 0.01M PBS, 0.05% Tween-20, and 0.02% sodium azide preservative, pH 7.4) provided in the kit. Horseradish peroxidase (HRP)-labeled rabbit anti-zebrafish GABA polyclonal antibody enzyme-linked immunosorbent assay (1:5000 dilution) was added for further incubation. After washing with buffer, the fish were incubated at 37°C in the dark for 15 min for color development (the colorimetric reagent was: TMB colorimetric solution A (TMB substrate, 2 mg / mL) + solution B (0.02% H2O2, oxidant), 1:1). (Equal volumes were mixed), the solution changed from colorless to blue, then stop solution (2M H2SO4, 50 μL / well) was added, after which the solution turned yellow. After stabilizing for 10 min, the absorbance of each well was measured at 450 nm using a SpectraMax i3x microplate reader (Shanghai Flash Spectrum Biotechnology Co., Ltd.). A standard curve was plotted based on the standard concentration and absorbance to calculate the GABA content of each group. The standard concentration gradients were 0.05 μg / mL, 0.1 μg / mL, 0.2 μg / mL, 0.5 μg / mL, 1 μg / mL, 2 μg / mL, 5 μg / mL, and 10 μg / mL, for a total of 8 concentration points. The fitted curve equation is as follows:

[0294]

[0295] The goodness of fit of the obtained equation R 2 =0.998.

[0296] The meanings of the parameters in the equation are as follows:

[0297] y: Corrected absorbance (A450-630, i.e., absorbance at the main wavelength of 450nm minus absorbance at the reference wavelength of 630nm);

[0298] x: Concentration of GABA standard (μg / mL);

[0299] A: Maximum absorbance (upper limit of plateau period) ≈ 1.92;

[0300] B: Curve slope factor (response sensitivity) ≈ 1.45;

[0301] C: Half-maximal effect concentration (EC5) 50 The concentration at which the absorbance reaches (AD) / 2 is approximately 0.78 μg / mL;

[0302] D: Minimum absorbance (background signal) ≈ 0.12

[0303] 5. Test Results

[0304] 5.1 Determination of Maximum Detectable Concentration (MTC)

[0305] Figures 7A-7D The survival rate, heart rate, deformity rate, and phenotypic changes of zebrafish exposed to different concentrations of samples for 96 h were displayed. (Results were statistically analyzed using one-way ANOVA. * indicates P < 0.05, and ns indicates no significant difference compared to the control group.)

[0306] Depend on Figures 7A-7D The results showed that after 96 hours of exposure to different concentrations of samples, zebrafish at 5 dpf had a survival rate of approximately 90% at the 1000 μg / mL concentration, which was significantly lower than the control. However, the survival rates of zebrafish in the other groups were not significantly different from the control. Figure 7A The heart rate of zebrafish in each group did not change significantly compared to the control group. Figure 7B Except for the zebrafish that showed a certain rate of deformity at the highest concentration, ( Figure 7C (Approximately 10%), no abnormalities were observed at the remaining concentrations, and no significant changes in phenotype were observed at different concentrations. Figure 7D Therefore, the above experimental results confirm that zebrafish exhibited high safety after 96 hours of exposure to different concentrations of samples, with only a slight decrease in survival rate and deformities observed at the highest concentration. To better reflect the sleep-promoting effect of the samples, we subsequently selected a sample composition concentration of 500 μg / mL for related efficacy tests.

[0307] 5.2 Behavioral Testing

[0308] Figures 8A-8D This displays the statistical analysis of autonomous behavior in zebrafish after different sample treatments. (Results were statistically analyzed using one-way ANOVA. Compared with the control group, * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, and ns indicates no significant difference.)

[0309] Depend on Figures 8A-8D It can be seen that, compared with the control group, the total arousal activity of zebrafish in the model group was significantly increased. Figure 8A ), Total Awakening Time ( Figure 8B The number of awakening rounds has increased significantly. Figure 8C ), sleep latency was significantly prolonged ( Figure 8D This indicates that the zebrafish model was successful. After treatment with different compositions (compositions 1, 2, and 3), the total amount of arousal movement in the zebrafish ( Figure 8A ), Total Awakening Time ( Figure 8B ), number of awakening rounds ( Figure 8C ) and sleep latency ( Figure 8D Compared with the model group, all compositions showed varying degrees of improvement, especially composition 1, which showed a highly significant improvement in all sleep indicators (P < 0.001). Composition 2 also achieved good improvements in various sleep indicators, with a highly significant improvement in total wakefulness-motor activity (P < 0.001), a very significant improvement in total wakefulness time (P < 0.01), and significant improvements in the number of wakefulness rounds and sleep latency (P < 0.05). Composition 3, except for no significant improvement in the number of wakefulness rounds, also showed good improvement in wakefulness-motor activity, total wakefulness time, and sleep latency (P < 0.001, < 0.01, and < 0.01, respectively).

[0310] The specific values ​​for the improvement of sleep indicators by compositions 1, 2, and 3 are shown in Table 9. The improvement rates of composition 1 were: 57.33% improvement in total wakefulness activity, 43.98% improvement in total wakefulness time, 27.14% improvement in the number of wakefulness rounds, and 41.43% improvement in sleep latency; the corresponding improvement rates for composition 2 were 35.49%, 18.00%, 17.14%, and 16.57%; and the corresponding improvement rates for composition 3 were 32.33%, 17.66%, 14.29%, and 19.12%. The above effects of the sample groups (especially composition 1) were even close to those of the positive control melatonin. It can be seen from the above that the three compositions prepared by different ratios of γ-aminobutyric acid (GABA) and L-theanine can effectively reduce the amount of activity after wakefulness in zebrafish, shorten the wakefulness time, reduce the number of wakefulness rounds, and shorten the time to fall asleep, thus having the effect of improving the sleep status of zebrafish with sleep disorders.

[0311] 5.3 Detection of relative expression levels of GABA-A receptor gene

[0312] Figure 9 This shows the relative expression levels of the GABA-A receptor gene in zebrafish under different sample exposure conditions. (Statistical analysis was performed using one-way ANOVA. Compared with the model group, * indicates P < 0.05, *** indicates P < 0.001, and ns indicates no significant difference.)

[0313] like Figure 9The results showed that, compared with the control group, the relative expression level of the GABA-A receptor gene in the model group zebrafish was significantly lower than that in the control group (P < 0.001), indicating that the zebrafish animal model was successfully established. Compared with the model group, the relative expression level of the GABA-A receptor gene in zebrafish treated with the three compositions increased to varying degrees. Composition 1 increased by 18.52%, showing the most significant effect (P < 0.001), composition 2 increased by 10.07%, but the improvement was not significant, while composition 3 increased by 13.56% compared with the control, which was also significant (P < 0.05). These data indicate that all three compositions can, to some extent, increase the expression level of the GABA-A receptor in zebrafish with sleep disorders, thereby inhibiting nerve excitation and improving sleep.

[0314] 5.4 GABA content detection

[0315] Figure 10 This shows the GABA content in zebrafish exposed to different samples. (Statistical analysis was performed using one-way ANOVA. Compared with the model, * indicates P < 0.05, ** indicates P < 0.01, and ns indicates no significant difference.)

[0316] like Figure 10 The results showed that, compared with the control group, the GABA content in the model group of zebrafish was significantly lower than that in the control group (P < 0.001), indicating that the zebrafish animal model was successfully established. Compared with the model group, the GABA content in zebrafish treated with the three compositions increased to some extent. Among them, compositions 1 and 2 promoted the increase of GABA content in zebrafish by 31.33% and 24.14%, respectively (Table 9), and the differences from the model group were statistically significant (composition 1, P < 0.01; composition 2, P < 0.05). Although composition 3 also promoted the increase of GABA content in zebrafish to some extent (21.59%), its improvement effect did not reach a statistically significant level. The above results indicate that the three compositions with different active ingredient ratios can increase the GABA content in zebrafish, inhibit nerve excitation, and thus improve the sleep state of zebrafish.

[0317] Table 9: Improvement rates of sleep-related indicators by the composition

[0318]

[0319] Note:

[0320] The above experimental results demonstrate that product compositions 1, 2, and 3 can effectively reduce the total arousal activity, decrease the total arousal time and number of arousal rounds in model zebrafish, shorten the sleep latency, increase the relative expression level of the GABA-A receptor gene in zebrafish, and increase the GABA content in the body, thereby inhibiting nerve excitation and promoting sleep in zebrafish. Among compositions 1, 2, and 3, composition 1 shows the most significant effect on improving sleep, followed by compositions 2 and 3.

[0321] Evaluation Example 2: Real-world population trial of sleep-promoting efficacy

[0322] 1. Test Subjects. A total of 31 subjects were recruited for the population trial, aged 19-55 years, with a mean age of 33 years. All subjects had varying degrees of sleep disturbances and poor sleep quality, with a Pittsburgh Sleep Quality Index (PSQI) score ≥8. Furthermore, none of the subjects had any known chronic diseases or diseases currently under treatment. Subjects voluntarily participated in the trial, signed informed consent forms, and indicated their willingness to comply with all evaluation requirements during the testing process. Subjects used the provided samples as required during the test and did not change any other lifestyle or dietary habits, nor use any other medications or products that might affect sleep.

[0323] 2. Test sample: Composition 1 produced according to the method in Example 1 was packaged in a minimum specification of 10g per bag.

[0324] Take one sachet (10 grams) of Composition 1 and dissolve it in 100 mL of warm water (approximately 50 degrees Celsius). Drink it 60 minutes before bedtime, once daily. Subjects evaluated their experience using the product on days 7, 14, and 28 (after 7, 14, and 28 days of use). Additionally, the Pittsburgh Sleep Quality Index, widely used in clinical practice, was used to assess the subjects' sleep quality before and after product use.

[0325] 3. Test Results

[0326] 3.1 Subjects' feelings and acceptance after using the sample

[0327] No adverse reactions were observed in the subjects after using Composition 1 for 7, 14, and 28 days, and the subjects reported that the product had a good taste and good dissolving properties. Subjects' self-reported feelings after using the sample are shown in the table below. Figure 11The percentage of respondents who rated the product as "No" for adverse reactions, "Good" for taste / mixability, and 4 or higher on other questionnaires (4 and 5 points) represents the proportion of those who rated the product as "Good". D7, D14, and D28 represent the results after 7, 14, and 28 days of product use, respectively. Adverse reactions, taste, and mixability were only evaluated at the end of the test (D28). Figure 11 The data shows that after 7 days of use, over 85% of the subjects reported improved sleep, indicating that most experienced sleep-promoting effects after just 7 days. Specifically, this manifested as faster sleep onset, better sleep quality, increased energy upon waking, a feeling of relaxation and well-being, deeper sleep, reduced waking, fewer dreams, and improved sleep anxiety, resulting in improved complexion and more radiant skin. After 14 and 28 days, even more subjects (>90%) recognized the product's sleep-promoting effects. In particular, after 28 days, almost all subjects (100%) reported that the product helped them sleep better, fall asleep faster, feel relaxed and well-being, improve sleep quality, soothe emotions, help them enter deep sleep, provide a calming and soothing effect, reduce sleep anxiety, and improve skin radiance. It is worth noting that some effects improved very quickly. For example, after using the product for 7 days, the vast majority of participants agreed that the product helped them sleep better and made them feel relaxed and happy. On the other hand, the acceptance of some effects continued to increase. For example, the acceptance of improvements in falling asleep, entering deep sleep, reducing dreams, calming and soothing hypnotic effects, improving sleep anxiety, and improving skin radiance increased at 7, 14, and 28 days. This also shows that these effects continued to appear as the participants used the product.

[0328] 3.2 Pittsburgh Sleep Index

[0329] The Pittsburgh Sleep Index scores of the subjects before and 28 days after product use are shown in Table 10. Figure 12 (*** indicates a highly significant difference before and after 28 days of use of Composition 1, P < 0.001). As shown, the Pittsburgh Sleep Quality Index (PSI) of the subjects before using the product ranged from 8 to 15, indicating mild to moderate sleep disturbances. After 28 days of product use, the subjects' PSI scores ranged from 1 to 12, indicating that some subjects' sleep quality had improved from mild or moderate sleep disturbances to a good state. The average PSI before product use was 10.9, and after product use it was 6.2, meaning it improved from near the average level of moderate sleep disturbance to near the average level of good sleep, an improvement rate of 43.12%, which was statistically significant (p < 0.001).

[0330] Table 10. Subjective Evaluation of Pittsburgh Sleep Quality Index

[0331]

[0332] Note: A higher Pittsburgh Sleep Quality Index (PSI) score indicates a more severe sleep disorder. A score ≤ 5 indicates good sleep quality, falling within the normal sleep range; a score of 6-10 indicates mild sleep disorder; a score of 11-15 indicates moderate sleep disorder; and a score ≥ 16 indicates severe sleep disorder. Improvement rate = (Pittsburgh Sleep Quality Index before product use - Pittsburgh Sleep Quality Index after product use) / Pittsburgh Sleep Quality Index before product use * 100%.

[0333] The above subject data indicate that Composition 1 has a significant sleep-promoting effect, significantly reducing the Pittsburgh Sleep Quality Index and noticeably improving sleep quality. Specifically, it improves sleep quality, helps the subject fall asleep faster, increases deep sleep, reduces dreams, promotes relaxation and pleasure, reduces sleep anxiety, improves complexion, and enhances skin radiance.

[0334] The above description is merely an exemplary embodiment of the present invention. It should be noted that those skilled in the art can make improvements to the present invention without departing from the inventive concept, and all such improvements fall within the scope of protection of the present invention.

Claims

1. A nutritional composition comprising or consisting of the following: Milk base powder of 90-95% by weight, selected from one or more of the following: whole milk powder, milk protein powder, bovine colostrum powder, whey protein powder, demineralized whey powder, and skim milk powder. 0.5-6.0% by mass of γ-aminobutyric acid, 0.5-6.0% L-theanine by mass 0.5-4% sodium carboxymethyl cellulose by weight, 0.05-1.0% by mass of silicon dioxide, 0.01-1.0% by weight of milk protein peptides, 0.01-1.0% by weight of colostrum peptide powder, 0.05-1.0% by weight of compound plant extracts, 0.01-1.0% by weight of a sweetener selected from steviol glycosides and / or mogrosides.

2. The nutritional composition of claim 1, wherein the nutritional composition comprises 1-3% by mass, for example 2% by mass, of γ-aminobutyric acid.

3. The nutritional composition according to any one of claims 1-2, wherein the nutritional composition comprises 1-3% by mass, for example 2% by mass, of L-theanine.

4. The nutritional composition according to any one of claims 1-3, wherein the mass ratio of γ-aminobutyric acid to L-theanine is 6:1-1:6, preferably 3:1 to 1:3, more preferably 3:1 to 1:1, and even more preferably 1:

1.

5. The nutritional composition according to any one of claims 1-4, wherein the sweetener is steviol glycoside, or a combination of steviol glycoside and mogroside, preferably steviol glycoside.

6. The nutritional composition according to any one of claims 1-5, wherein the nutritional composition comprises: 93-94% quality emulsion base powder, 1.9-2.1% by mass of γ-aminobutyric acid, 1.9-2.1% L-theanine by mass 1.4-1.6% sodium carboxymethyl cellulose by weight 0.15-0.25% silica by mass 0.05-0.15% by weight of milk protein peptides, 0.05-0.15% colostrum peptide powder by weight, 0.10-0.20% by weight of compound plant extracts, 0.05-0.15% by weight of steviol glycosides.

7. The nutritional composition according to any one of claims 1-6, wherein the compound plant extract comprises or is two or more of the following: tea theanine, lily powder, passion fruit powder, jujube seed powder, and saffron extract, preferably comprising or is tea theanine, lily powder, passion fruit powder, jujube seed powder, and saffron extract; preferably wherein the mass ratio of tea theanine: lily powder: passion fruit powder: jujube seed powder: saffron extract is (0.5-4.0):1: (0.5-2.0):(0.5-2.0):(0.05-1.0), more preferably (1.0-2.0):1: (0.5-1.0):(0.5-1.5):(0.1-0.5), and more preferably 1.6:1:0.8:1:0.

2.

8. A method for preparing the nutritional composition according to any one of claims 1-7, comprising the following steps: (1) Ingredients: Provide the formula amount of milk base powder, γ-aminobutyric acid, L-theanine, sodium carboxymethyl cellulose, silicon dioxide, milk protein peptides, colostrum peptide powder, compound plant extracts and sweeteners; (2) Premixed: (2-1) Disperse and granulate the formulated amounts of silica, milk protein peptides, colostrum peptide powder, compound plant extracts, and sweeteners to obtain premix A; and (2-2) Disperse and granulate the formulated amounts of γ-aminobutyric acid and L-theanine to obtain premix B; (3) Sieving: The emulsion base powder, premix A, premix B, and sodium carboxymethyl cellulose are passed through a vibrating screen in n batches. The resulting materials enter the mixing drum. - n is a positive integer of 3 or greater. - Sodium carboxymethyl cellulose is added in the i-th batch, where i is a positive integer ≤ n / 2; - In each of batches 1 to n-2, when sodium carboxymethyl cellulose is not present, the ingredients are added in the order of 1 / n formula amount of emulsion powder, 1 / n formula amount of premix A, and 1 / n formula amount of premix B; and when sodium carboxymethyl cellulose is present, the ingredients are added in the order of 1 / n formula amount of emulsion powder, 1 / n formula amount of premix A, 1 / n formula amount of premix B, and formula amount of sodium carboxymethyl cellulose. -In the n-1th batch, the emulsion base powder (1 / 2n of the formula amount), premix A (1 / n of the formula amount), and premix B (1 / n of the formula amount) are added in that order; -In the nth batch, the ingredients are added in the following order: 1 / 2n of the formula amount of emulsion base powder, 1 / n of the formula amount of premix A, 1 / n of the formula amount of premix B, and 1 / n of the formula amount of emulsion base powder. (4) Dry mixing: The materials obtained in the mixing cylinder in step (3) are dry mixed to obtain the nutritional composition.

9. The method of claim 8, wherein the granulation in steps (2-1) and (2-2) is performed at the same or different, preferably the same, operating frequencies and said operating frequencies are each independently 10-60 Hz, for example 30-35 Hz; the granulation in steps (2-1) and (2-2) is performed using the same or different, preferably the same, sieves and said sieves are each independently 10-60 mesh, for example 20-40 mesh.

10. The method of any one of claims 8-9, wherein n=3, and in step (3), the emulsion base powder, premix A, premix B and sodium carboxymethyl cellulose are added in the following order: Batch 1: 1 / 3 of the formula amount of emulsion base powder, 1 / 3 of the formula amount of premix A, 1 / 3 of the formula amount of premix B, and the formula amount of sodium carboxymethyl cellulose. Batch 2: 1 / 6 of the formula amount of emulsion base powder, 1 / 3 of the formula amount of premix A, and 1 / 3 of the formula amount of premix B. Batch 3: 1 / 6 of the formula amount of emulsion base powder, 1 / 3 of the formula amount of premix A, 1 / 3 of the formula amount of premix B, and 1 / 3 of the formula amount of emulsion base powder.

11. The method according to any one of claims 8-10, wherein n=4, and in step (3), the emulsion base powder, premix A, premix B and sodium carboxymethyl cellulose are added in the following order: Batch 1: 1 / 4 of the formula amount of milk base, 1 / 4 of the formula amount of premix A, and 1 / 4 of the formula amount of premix B. Batch 2: 1 / 4 of the formula amount of base material, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, and sodium carboxymethyl cellulose. Batch 3: 1 / 8 of the formula amount of base material, 1 / 4 of the formula amount of premix A, and 1 / 4 of the formula amount of premix B. Batch 4: 1 / 8 of the formula amount of base material, 1 / 4 of the formula amount of premix A, 1 / 4 of the formula amount of premix B, and 1 / 4 of the formula amount of base material.

12. The method according to any one of claims 8-11, wherein the vibrating sieve used in step (3) is 10-30 mesh.

13. Use of the nutritional composition as described in any one of claims 1-7 or as prepared by the method of any one of claims 8-12 in improving sleep.

Images